Empagliflozin [864070-44-0]

Name: Empagliflozin [864070-44-0]
SKU: AG-CR1-3619_A27
Availability: BackOrder

AG-CR1-3619

CAS Number864070-44-0

Product group Chemicals

Estimated Purity>98%

Molecular Weight450.9

Overview

Supplier
AdipoGen Life Sciences
Product Name
Empagliflozin [864070-44-0]
Delivery Days Customer
10
CAS Number
864070-44-0
Certification
Research Use Only
Estimated Purity
>98%
Hazard Information
Warning
Molecular Formula
C23H27ClO7
Molecular Weight
450.9
Scientific Description
Antidiabetic agent. Potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor. >300-fold selectivity over SGLT-1, 4, 5 and 6. SGLT-2 is found almost exclusively in the proximal tubules of nephronic components in kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Shown to preserves beta cell mass and restore glucose homeostasis. - Chemical. CAS: 864070-44-0. Formula: C23H27ClO7. MW: 450.9. Antidiabetic agent. Potent and selective sodium glucose co-transporter 2 (SGLT-2) inhibitor. >300-fold selectivity over SGLT-1, 4, 5 and 6. SGLT-2 is found almost exclusively in the proximal tubules of nephronic components in kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Shown to preserves beta cell mass and restore glucose homeostasis.
SMILES
OCC1O[C@H](C(O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1
Storage Instruction
2°C to 8°C,-20°C
UNSPSC
12352200

BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus: I. Aires & J. Calado; Curr. Opin. Investig. Drugs 11, 1182 (2010)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors: R. Grempler, et al.; Diabetes Obes. Metab. 14, 83 (2012)
Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats: L. Thomas, et al.; Diabetes Obes. Metab. 14, 94 (2012)
Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. L. Seman, et al.; Clin. Pharmacol. Drug Dev. 2, 152 (2013)
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review: J.B. McGill; Diabetes Ther. 5, 43 (2014) (Review)
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes: E.M. Lamos, et al.; Expert Opin. Investig. Drugs 23, 875 (2014) (Review)
The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat: H.H. Hansen, et al.; J. Pharmacol. Exp. Ther. 350, 657 (2014)